查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930167

全球治療性神經毒素市場：市場規模、佔有率、成長率、產業分析、類型、應用、區域因素及未來預測（2026-2034）

Therapeutic Neurotoxin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 309 Pages | 商品交期: 請詢問到貨日

價格

治療性神經毒素市場成長因素

受神經系統疾病盛行率上升、治療適應症不斷擴大以及肉毒桿菌毒素療法持續獲得監管部門批准等因素的推動，全球治療性神經毒素市場呈現強勁且持續的成長態勢。 2025年，該市場價值為63.4億美元，預計到2026年將成長至68.6億美元。在長期預測期內，預計到2034年，該市場將達到133.9億美元，反映出神經毒素療法在多種神經系統和神經肌肉疾病中的應用日益廣泛。

治療性神經毒素主要為A型和B型肉毒桿菌毒素，來自肉毒梭菌。這些神經毒素透過抑制神經肌肉接頭處乙醯膽鹼的釋放來發揮作用，從而導致肌肉暫時性鬆弛。這種作用機制已被證明在治療慢性偏頭痛、痙攣、頸肌張力失調、眼瞼痙攣和膀胱過動症等疾病方面非常有效。人口老化和全球神經系統疾病負擔的加重是推動治療性神經毒素臨床應用擴大的關鍵因素。

市場概覽及關鍵洞察

預計2025年，北美將以61.39%的市佔率主導治療性神經毒素市場，區域市場價值達46億美元。這一主導地位得益於先進的醫療基礎設施、較高的疾病認知度、有利的報銷制度以及對新型神經毒素療法的早期應用。美國之所以引領區域市場，是因為其擁有眾多大型企業、較高的治療接受度以及不斷擴大的適應症獲得監管部門的批准。預計到2026年，光是美國市場規模就將達到48.6億美元。

歐洲是第二大區域市場，其成長主要受中風相關痙攣、慢性偏頭痛和肌張力失調病例增加以及積極的研發活動所驅動。 由於神經系統疾病盛行率上升、專業治療途徑的擴大以及日本、中國和印度等國家醫療保健投資的增加，預計亞太地區將實現最快成長。

市場動態

市場驅動因素

神經系統疾病盛行率的上升是治療性神經毒素市場的主要驅動因素。根據世界衛生組織 (WHO) 統計，2021 年全球約 40.0% 的人口（約 31 億人）受到頭痛疾病的影響。慢性偏頭痛患者已從肉毒桿菌療法中獲益匪淺，該療法可降低頭痛的頻率和嚴重程度。此外，痙攣、頸部肌張力失調和中風後併發症病例的增加也推動了對基於神經毒素的療法的需求。

市場限制因子

高昂的治療費用和潛在的副作用限制了其在成本敏感地區的廣泛應用。 肉毒桿菌治療慢性偏頭痛每年費用約為 3,000 美元，每三個月注射一次，這會造成經濟負擔。肌肉無力、頸部疼痛和眼瞼下垂等副作用會進一步降低患者的依從性，並在某些情況下影響醫生對該療法的接受度。

市場機會

將神經毒素的臨床應用擴展到傳統神經系統疾病之外，蘊藏著巨大的機會。越來越多的研究表明，A 型肉毒桿菌可能有助於治療憂鬱症、創傷後壓力症候群 (PTSD)、神經性疼痛和社交焦慮症。神經毒素具有療效持久、給藥頻率低等優勢，有助於提高患者的依從性。探索神經精神疾病的臨床試驗進展有望擴大治療性神經毒素的商業範圍。

市場挑戰

生物相似藥的興起對現有品牌構成了挑戰。生物相似藥以更低的成本提供相當的療效，導致價格競爭加劇。 生物相似藥的監管路徑日趨清晰，這鼓勵了新進入者，並進一步加劇了市場競爭。

市場趨勢

影響市場的一大趨勢是開發替代性的無針給藥系統。各公司正在探索局部和皮內給藥等方法，以提高患者的舒適度，尤其是在原發性腋窩多汗症等疾病。這些創新旨在減少注射相關的焦慮，並擴大患者接受神經毒素治療的機會。

市場區隔分析

依類型

截至2024年，A型肉毒桿菌細分市場佔主導地位，這得益於多種已核准的產品和不斷擴大的治療適應症。 Xeomin和Botox等產品的監管批准將繼續推動該細分市場的成長。 B型肉毒桿菌毒素由於核准產品數量有限，市場佔有率較小，但正在進行的臨床試驗可能會支持其未來的擴張。

依應用領域

痙攣領域佔最大的市場佔有率，這主要得益於肌肉痙攣盛行率的上升以及針對特定肌肉群的適應症範圍擴大並獲得監管部門批准。慢性偏頭痛領域佔第二大市場佔有率，這主要得益於全球龐大的偏頭痛患者群。頸部肌張力失調和膀胱過動症領域也因公眾意識的提高和適應症範圍的擴大而穩步增長。

依最終使用者

由於神經治療患者數量的增加以及報銷的神經毒素療法的可及性提高，醫院在最終用戶領域佔主導地位。擁有先進基礎設施的專科診所也透過提供重症監護服務佔了相當大的市場。

"全球治療性神經毒素市場" 報告對2025年、2026年和2034年的市場規模和價值進行了全面分析，並深入探討了市場動態、市場細分、區域展望、競爭格局、研發管線、定價分析和關鍵行業趨勢。該報告重點闡述了不斷變化的監管環境、不斷擴大的治療適應症以及給藥技術的創新將如何塑造全球治療性神經毒素市場的未來。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家治療量概覽
  • 主要國家/地區監管概覽
  • 主要國家/地區報銷概覽
  • 主要公司新產品上市
  • 主要公司研發管線分析

第五章：全球治療性神經毒素市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型劃分
    • A型肉毒桿菌毒素
    • B型肉毒桿菌
  • 市場分析、洞察與預測：依應用劃分
    • 額紋
    • 眉間紋
    • 魚尾紋
    • 其他
  • 市場分析、洞察與預測：依最終用戶劃分
    • 專科診所及皮膚科診所
    • 醫院和診所
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美治療性神經毒素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲治療性神經毒素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 烏克蘭
    • 歐洲其他地區

第八章 亞太地區治療性神經毒素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
    • 泰國
    • 台灣
    • 亞太其他地區

第九章：拉丁美洲治療性神經毒素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 智利
    • 哥倫比亞
    • 拉丁美洲其他地區

第十章：中東與非洲治療性神經毒素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 埃及
    • 伊朗
    • 土耳其
    • 黎巴嫩
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 世界市場佔有率分析(2025年)
  • 企業簡介
    • AbbVie Inc.(Allergen Therapeutics)
    • Ipsen Pharma
    • Merz Pharma
    • HUGEL, Inc.
    • Evolus, Inc.
    • GALDERMA
    • REVANCE
    • Supernus Pharmaceuticals, Inc.
    • Shanghai Fosun Pharmaceutical(Group)Co., Ltd.
    • DAEWOONG PHARMACEUTICAL CO., LTD
Product Code: FBI113754

Growth Factors of therapeutic neurotoxin Market

The global therapeutic neurotoxin market is demonstrating strong and sustained growth, driven by the rising prevalence of neurological disorders, expanding therapeutic indications, and continuous regulatory approvals for botulinum toxin-based treatments. According to the 2025 report year, the market was valued at USD 6.34 billion in 2025 and is projected to grow to USD 6.86 billion in 2026. Over the long-term forecast period, the market is expected to reach USD 13.39 billion by 2034, reflecting increasing adoption of neurotoxin therapies across multiple neurological and neuromuscular conditions.

Therapeutic neurotoxins, primarily botulinum toxin type A and type B, are derived from Clostridium botulinum. These neurotoxins act by inhibiting acetylcholine release at the neuromuscular junction, resulting in temporary muscle relaxation. This mechanism has proven highly effective in managing conditions such as chronic migraine, spasticity, cervical dystonia, blepharospasm, and overactive bladder. The expanding elderly population and growing global burden of neurological diseases are key contributors to the increasing clinical utilization of therapeutic neurotoxins.

Market Overview and Key Insights

In 2025, North America dominated the therapeutic neurotoxin market with a market share of 61.39%, accounting for a regional market value of USD 4.6 billion. This dominance is supported by advanced healthcare infrastructure, high disease awareness, favorable reimbursement frameworks, and early adoption of novel neurotoxin therapies. The U.S. leads the regional market due to strong presence of key players, high treatment acceptance, and continuous regulatory approvals for expanded indications. The U.S. market alone is projected to reach USD 4.86 billion by 2026.

Europe represents the second-largest regional market, driven by rising cases of stroke-related spasticity, chronic migraine, and dystonia, along with strong research and development activities. Asia Pacific is expected to witness the fastest growth, supported by increasing neurological disease prevalence, expanding access to specialized treatments, and rising healthcare investments in countries such as Japan, China, and India.

Market Dynamics

Market Drivers

The increasing prevalence of neurological disorders is a major driver for the therapeutic neurotoxin market. According to the World Health Organization, headache disorders affected approximately 40.0% of the global population in 2021, equivalent to nearly 3.10 billion people. Chronic migraine patients benefit significantly from botulinum toxin therapy, which reduces headache frequency and severity. Additionally, rising cases of spasticity, cervical dystonia, and post-stroke complications are increasing demand for neurotoxin-based interventions.

Market Restraints

High treatment costs and potential side effects limit broader adoption in cost-sensitive regions. Botox therapy for chronic migraine, administered every three months, can cost around USD 3,000 annually, which poses affordability challenges. Side effects such as muscle weakness, neck pain, and eyelid ptosis further restrict patient compliance and physician adoption in certain cases.

Market Opportunities

Expanding clinical applications of neurotoxins beyond traditional neurological disorders presents significant opportunities. Emerging research highlights the potential use of botulinum toxin A in treating depression, PTSD, neuropathic pain, and social anxiety disorders. Neurotoxins offer advantages such as long-lasting effects and reduced dosing frequency, improving patient adherence. Ongoing clinical trials exploring neuropsychiatric indications are expected to broaden the commercial scope of therapeutic neurotoxins.

Market Challenges

The growing presence of biosimilar neurotoxins poses a challenge to established brands. Biosimilars offer comparable efficacy at lower costs, increasing price competition. Regulatory pathways for biosimilars are becoming more defined, encouraging new entrants and intensifying market competition.

Market Trends

A prominent trend shaping the market is the development of needle-free and alternative delivery systems. Companies are exploring topical and intradermal delivery methods to improve patient comfort, particularly for conditions such as primary axillary hyperhidrosis. These innovations aim to reduce injection-related anxiety and expand patient access to neurotoxin therapies.

Segmentation Analysis

By Type

The botulinum toxin type A segment dominated the market in 2024 due to the availability of multiple approved products and expanded therapeutic indications. Regulatory approvals for products such as Xeomin and Botox continue to support segment growth. Botulinum toxin type B holds a smaller share, limited by fewer approved products, though ongoing clinical trials may support future expansion.

By Application

The spasticity segment holds the largest market share, driven by increasing prevalence of muscle spasticity and rising regulatory approvals for expanded muscle group indications. The chronic migraine segment represents the second-largest share, supported by the large global migraine population. Cervical dystonia and overactive bladder segments are also expanding steadily due to growing awareness and approvals.

By End User

Hospitals dominate the end-user segment due to higher patient inflow for neurological treatments and improved access to reimbursed neurotoxin therapies. Specialty clinics hold a significant share, offering focused care with advanced infrastructure.

Competitive Landscape

The therapeutic neurotoxin market is highly consolidated, led by AbbVie Inc., Ipsen Pharma, and Merz Pharma. AbbVie's strong portfolio, including BOTOX Therapeutic, positions it as a market leader. Other players such as Revance Therapeutics, Medytox, and Hugel are strengthening their presence through product launches, regulatory approvals, and strategic collaborations.

Report Coverage

The therapeutic neurotoxin market report provides a comprehensive analysis of market size and value for 2025, 2026, and 2034, along with in-depth insights into market dynamics, segmentation, regional outlook, competitive landscape, pipeline developments, pricing analysis, and key industry trends. The report emphasizes regulatory progress, expanding therapeutic indications, and innovation in delivery technologies shaping the future of the global therapeutic neurotoxin market.

Conclusion

The therapeutic neurotoxin market is positioned for robust and sustained growth over the forecast period, supported by the expanding burden of neurological disorders and the widening clinical acceptance of botulinum toxin-based therapies. With the market valued at USD 6.34 billion in 2025, projected to increase to USD 6.86 billion in 2026, and expected to reach USD 13.39 billion by 2034, the outlook reflects strong demand across indications such as spasticity, chronic migraine, cervical dystonia, and overactive bladder. North America's dominance, holding 61.39% market share in 2025, underscores the role of advanced healthcare infrastructure, favorable reimbursement, and frequent regulatory approvals, while Asia Pacific is emerging as a high-growth region driven by rising disease prevalence and healthcare investment. Despite challenges related to high treatment costs, side effects, and increasing biosimilar competition, continuous innovation in delivery methods, expanding therapeutic applications-including neuropsychiatric conditions-and sustained R&D investments by leading players are strengthening long-term market fundamentals. Overall, the therapeutic neurotoxin market is expected to maintain strong momentum through 2034, driven by clinical efficacy, expanding indications, and evolving treatment technologies.

Segmentation By Type

  • Botulinum Toxin Type A
  • Botulinum Toxin Type B

By Application

  • Chronic Migraine
  • Spasticity
  • Overactive Bladder
  • Cervical Dystonia
  • Blepharospasm
  • Others

By End-user

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America (By Type, Application, End-user, and Country)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Type, Application, End-user, and Country/Sub-Region)
    • U.K. (By Application)
    • Germany (By Application)
    • France (By Application)
    • Italy (By Application)
    • Spain (By Application)
    • Scandinavia (By Application)
    • Ukraine (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Type, Application, End-user, and Country/Sub-Region)
    • Japan (By Application)
    • China (By Application)
    • India (By Application)
    • Australia (By Application)
    • South Korea (By Application)
    • Thailand (By Application)
    • Taiwan (By Application)
    • Rest of Asia Pacific (By Application)
  • Latin America (By Type, Application, End-user, and Country/Sub-Region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Colombia (By Application)
    • Argentina (By Application)
    • Venezuela (By Application)
    • Chile (By Application)
    • Rest of Latin America (By Application)
  • Middle East & Africa (By Type, Application, End-user, and Country/Sub-Region)
    • UAE (By Application)
    • Saudi Arabia (By Application)
    • Turkey (By Application)
    • Egypt (By Application)
    • Lebanon (By Application)
    • Iran (By Application)
    • Rest of GCC (By Application)
    • South Africa (By Application)
    • Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of the Number of Therapeutic Procedures, By Key Countries
  • 4.2. Overview of Regulatory Scenario, By Key Countries
  • 4.3. Overview of Reimbursement Scenario, By Key Countries
  • 4.4. New Product Launches, By Key Players
  • 4.5. Pipeline Analysis, By Key Players

5. Global Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Botulinum Toxin Type A
    • 5.1.2. Botulinum Toxin Type B
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Forehead Wrinkles
    • 5.2.2. Glabellar Lines
    • 5.2.3. Crow's Feet
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-User
    • 5.3.1. Specialty & Dermatology Clinics
    • 5.3.2. Hospitals & Clinics
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Botulinum Toxin Type A
    • 6.1.2. Botulinum Toxin Type B
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Forehead Wrinkles
    • 6.2.2. Glabellar Lines
    • 6.2.3. Crow's Feet
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-User
    • 6.3.1. Specialty & Dermatology Clinics
    • 6.3.2. Hospitals & Clinics
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Botulinum Toxin Type A
    • 7.1.2. Botulinum Toxin Type B
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Forehead Wrinkles
    • 7.2.2. Glabellar Lines
    • 7.2.3. Crow's Feet
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-User
    • 7.3.1. Specialty & Dermatology Clinics
    • 7.3.2. Hospitals & Clinics
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Ukraine
    • 7.4.8. Rest of Europe

8. Asia Pacific Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Botulinum Toxin Type A
    • 8.1.2. Botulinum Toxin Type B
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Forehead Wrinkles
    • 8.2.2. Glabellar Lines
    • 8.2.3. Crow's Feet
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-User
    • 8.3.1. Specialty & Dermatology Clinics
    • 8.3.2. Hospitals & Clinics
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. South Korea
    • 8.4.6. Thailand
    • 8.4.7. Taiwan
    • 8.4.8. Rest of Asia Pacific

9. Latin America Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Botulinum Toxin Type A
    • 9.1.2. Botulinum Toxin Type B
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Forehead Wrinkles
    • 9.2.2. Glabellar Lines
    • 9.2.3. Crow's Feet
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-User
    • 9.3.1. Specialty & Dermatology Clinics
    • 9.3.2. Hospitals & Clinics
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Chile
    • 9.4.4. Colombia
    • 9.4.5. Rest of Latin America

10. Middle East & Africa Therapeutic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Botulinum Toxin Type A
    • 10.1.2. Botulinum Toxin Type B
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Forehead Wrinkles
    • 10.2.2. Glabellar Lines
    • 10.2.3. Crow's Feet
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By End-User
    • 10.3.1. Specialty & Dermatology Clinics
    • 10.3.2. Hospitals & Clinics
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. Egypt
    • 10.4.2. Iran
    • 10.4.3. Turkey
    • 10.4.4. Lebanon
    • 10.4.5. UAE
    • 10.4.6. Saudi Arabia
    • 10.4.7. South Africa
    • 10.4.8. Rest of Middle East and Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. AbbVie Inc. (Allergen Therapeutics)
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Ipsen Pharma
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merz Pharma
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. HUGEL, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Evolus, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. GALDERMA
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. REVANCE
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Supernus Pharmaceuticals, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. DAEWOONG PHARMACEUTICAL CO., LTD
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 3: Global Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 4: Global Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 6: North America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 7: North America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 8: North America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 9: Europe Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 10: Europe Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 11: Europe Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 12: Europe Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Asia Pacific Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 15: Asia Pacific Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 16: Asia Pacific Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 17: Latin America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Latin America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Latin America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 20: Latin America Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Middle East & Africa Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 23: Middle East & Africa Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 24: Middle East & Africa Therapeutic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Therapeutic Neurotoxin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Therapeutic Neurotoxin Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Therapeutic Neurotoxin Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Therapeutic Neurotoxin Market Value Share (%), by End-User, 2025 & 2034
  • Figure 5: Global Therapeutic Neurotoxin Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Therapeutic Neurotoxin Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Therapeutic Neurotoxin Market Value Share (%), by Type, 2025
  • Figure 8: North America Therapeutic Neurotoxin Market Value (USD billion), by Application, 2025 & 2034
  • Figure 9: North America Therapeutic Neurotoxin Market Value Share (%), by Application, 2025
  • Figure 10: North America Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 11: North America Therapeutic Neurotoxin Market Value Share (%), by End-User, 2025
  • Figure 12: North America Therapeutic Neurotoxin Market Value (USD billion), by Country, 2025 & 2034
  • Figure 13: North America Therapeutic Neurotoxin Market Value Share (%), by Country, 2025
  • Figure 14: Europe Therapeutic Neurotoxin Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Therapeutic Neurotoxin Market Value Share (%), by Type, 2025
  • Figure 16: Europe Therapeutic Neurotoxin Market Value (USD billion), by Application, 2025 & 2034
  • Figure 17: Europe Therapeutic Neurotoxin Market Value Share (%), by Application, 2025
  • Figure 18: Europe Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 19: Europe Therapeutic Neurotoxin Market Value Share (%), by End-User, 2025
  • Figure 20: Europe Therapeutic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Therapeutic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Therapeutic Neurotoxin Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Therapeutic Neurotoxin Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Therapeutic Neurotoxin Market Value (USD billion), by Application, 2025 & 2034
  • Figure 25: Asia Pacific Therapeutic Neurotoxin Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 27: Asia Pacific Therapeutic Neurotoxin Market Value Share (%), by End-User, 2025
  • Figure 28: Asia Pacific Therapeutic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Therapeutic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Therapeutic Neurotoxin Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Latin America Therapeutic Neurotoxin Market Value Share (%), by Type, 2025
  • Figure 32: Latin America Therapeutic Neurotoxin Market Value (USD billion), by Application, 2025 & 2034
  • Figure 33: Latin America Therapeutic Neurotoxin Market Value Share (%), by Application, 2025
  • Figure 34: Latin America Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 35: Latin America Therapeutic Neurotoxin Market Value Share (%), by End-User, 2025
  • Figure 36: Latin America Therapeutic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Therapeutic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Therapeutic Neurotoxin Market Value (USD billion), by Type, 2025 & 2034
  • Figure 39: Middle East & Africa Therapeutic Neurotoxin Market Value Share (%), by Type, 2025
  • Figure 40: Middle East & Africa Therapeutic Neurotoxin Market Value (USD billion), by Application, 2025 & 2034
  • Figure 41: Middle East & Africa Therapeutic Neurotoxin Market Value Share (%), by Application, 2025
  • Figure 42: Middle East & Africa Therapeutic Neurotoxin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 43: Middle East & Africa Therapeutic Neurotoxin Market Value Share (%), by End-User, 2025
  • Figure 44: Middle East & Africa Therapeutic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Therapeutic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Therapeutic Neurotoxin Market Share (%), by Company, 2025